ABSTRACT
BACKGROUND Ovarian carcinosarcoma (OCS) is an uncommon, biphasic and highly aggressive ovarian cancer type, which has received relatively little research attention.
METHODS We curated the largest pathologically-confirmed OCS cohort to date, performing detailed histopathological characterisation, analysis of features associated with survival, and comparison against high grade serous ovarian carcinoma (HGSOC).
RESULTS 82 OCS patients were identified; overall survival was poor (median 12.7 months). 79% demonstrated epithelial components of high grade serous (HGS) type, while 21% were endometrioid. Heterologous elements were common (chondrosarcoma in 32%, rhabdomyosarcoma in 21%, liposarcoma in 2%); chondrosarcoma was more frequent in OCS with carcinomatous components of endometrioid type. Earlier stage, complete surgical resection, and treatment with platinum-containing chemotherapy were associated with prolonged survival; however, risk of relapse and mortality was high across all patient groups. Histological subclassification did not identify subgroups with distinct survival. Compared to HGSOC, OCS patients were older at diagnosis (P<0.0001), more likely to be FIGO stage I (P=0.025), demonstrated lower chemotherapy response rate (P=0.001) and had significantly poorer survival (P<0.0001).
CONCLUSION OCS represents a distinct, highly lethal form of ovarian cancer for which new treatment strategies are urgently needed. Aggressive adjuvant chemotherapy should be considered for all patients, including those with early stage disease.
Competing Interest Statement
RLH: consultancy fees from GSK outside the scope of this work. IC: none. MC: none. TR: none. CB: none. CG: grants from AstraZeneca, MSD, BMS, Clovis, Novartis, BerGenBio, Medannexin and Artios; personal fees from AstraZeneca, MSD, GSK, Tesaro, Clovis, Roche, Foundation One, Chugai, Takeda, Sierra Oncology, Takeda and Cor2Ed outside the submitted work; patents PCT/US2012/040805 issued, PCT/GB2013/053202 pending, 1409479.1 pending, 1409476.7 pending, and 1409478.3 pending. CSH: none.
Funding Statement
This work was supported by a Tenovus Scotland Grant awarded to RLH (E19-11), and by the Nicola Murray Foundation. CB is supported by funding from Cancer Research UK. Sample collection was supported by Cancer Research UK Experimental Cancer Medicine Centre funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was obtained from the Lothian NRS Human Annotated Bioresource (reference 15/ES/0094-SR1330) and the South East Scotland Cancer Information Research Governance Committee (reference CG/DF/E164-CIR21171). All participants gave written informed consent or had consent waived by the ethics committee due to the retrospective nature of the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by a Tenovus Scotland Grant awarded to RLH (ref E19-11), and by The Nicola Murray Foundation. CB is supported by funding from Cancer Research UK. Sample collection was supported by Cancer Research UK Experimental Cancer Medicine Centre funding
COIs: RLH: consultancy fees from GSK outside the scope of this work. IC: none. MC: none. TR: none. CB: none. CG: grants from AstraZeneca, MSD, BMS, Clovis, Novartis, BerGenBio, Medannexin and Artios; personal fees from AstraZeneca, MSD, GSK, Tesaro, Clovis, Roche, Foundation One, Chugai, Takeda, Sierra Oncology, Takeda and Cor2Ed outside the submitted work; patents PCT/US2012/040805 issued, PCT/GB2013/053202 pending, 1409479.1 pending, 1409476.7 pending, and 1409478.3 pending. CSH: none.
Data Availability
We are happy to provide relevant data upon reasonable request, subject to compliance with the relevant ethical framework.
